|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. In: Lung cancer and personalized medicine.
Springer. (New York, NY). 1–19. 2016.
|
|
3
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ettinger DS, Akerley W, Bepler G, Blum MG,
Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, et
al: Non-small cell lung cancer. J Natl Compr Canc Netw. 8:740–801.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang JS, Chen LT, Shan YS, Lin SF, Hsiao
SY, Tsai CR, Yu SJ and Tsai HJ: Comprehensive analysis of the
incidence and survival patterns of lung cancer by histologies,
including rare subtypes, in the era of molecular medicine and
targeted therapy: A nation-wide cancer registry-based study from
Taiwan. Medicine (Baltimore). 94:e9692015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ger LP, Liou SH, Shen CY, Kao SJ and Chen
KT: Risk factors of lung cancer. J Formos Med Assoc. 91 (Suppl
3):S222–S231. 1992.(In Japanese). PubMed/NCBI
|
|
7
|
Hirayasu T, Iwamasa T, Kamada Y, Koyanagi
Y, Usuda H and Genka K: Human papillomavirus DNA in squamous cell
carcinoma of the lung. J Clin Pathol. 49:810–817. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamamoto H, Shigematsu H, Nomura M,
Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong
KM, et al: PIK3CA mutations and copy number gains in human lung
cancers. Cancer Res. 68:6913–6921. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eberhard DA, Johnson BE, Amler LC, Goddard
AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson
DH, et al: Mutations in the epidermal growth factor receptor and in
KRAS are predictive and prognostic indicators in patients with
non-small-cell lung cancer treated with chemotherapy alone and in
combination with erlotinib. J Clin Oncol. 23:5900–5909. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Toyooka S, Tsuda T and Gazdar AF: The TP53
gene, tobacco exposure, and lung cancer. Hum Mutat. 21:229–239.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hainaut P and Pfeifer GP: Patterns of p53
G->T transversions in lung cancers reflect the primary mutagenic
signature of DNA-damage by tobacco smoke. Carcinogenesis.
22:367–374. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC,
Lin CW, Shih JY, Yang PC, Hsiao CK, Lai LC and Chuang EY:
Identification of a novel biomarker, SEMA5A, for non-small cell
lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers
Prev. 19:2590–2597. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ko PH, Lenka G, Chen YA, Chuang EY, Tsai
MH, Sher YP and Lai LC: Semaphorin 5A suppresses the proliferation
and migration of lung adenocarcinoma cells. Int J Oncol.
56:165–177. 2020.PubMed/NCBI
|
|
15
|
Unified nomenclature for the
semaphorins/collapsins. Semaphorin Nomenclature Committee. Cell.
97:551–552. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gherardi E, Love CA, Esnouf RM and Jones
EY: The sema domain. Curr Opin Struct Biol. 14:669–678. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hota PK and Buck M: Plexin structures are
coming: Opportunities for multilevel investigations of semaphorin
guidance receptors, their cell signaling mechanisms, and functions.
Cell Mol Life Sci. 69:3765–3805. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pasterkamp RJ and Giger RJ: Semaphorin
function in neural plasticity and disease. Curr Opin Neurobiol.
19:263–274. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Delaire S, Elhabazi A, Bensussan A and
Boumsell L: CD100 is a leukocyte semaphorin. Cell Mol Life Sci.
54:1265–1276. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bougeret C, Mansur IG, Dastot H, Schmid M,
Mahouy G, Bensussan A and Boumsell L: Increased surface expression
of a newly identified 150-kDa dimer early after human T lymphocyte
activation. J Immunol. 148:318–323. 1992.PubMed/NCBI
|
|
21
|
Gitler AD, Lu MM and Epstein JA: PlexinD1
and semaphorin signaling are required in endothelial cells for
cardiovascular development. Dev Cell. 7:107–116. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hayashi M, Nakashima T, Taniguchi M,
Kodama T, Kumanogoh A and Takayanagi H: Osteoprotection by
semaphorin 3A. Nature. 485:69–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roche J, Boldog F, Robinson M,
Varella-Garcia M, Swanton M, Waggoner B, Fishel R, Franklin W,
Gemmill R, Drabkin H, et al: Distinct 3p21.3 deletions in lung
cancer and identification of a new human semaphorin. Oncogene.
12:1289–1297. 1996.PubMed/NCBI
|
|
24
|
Basile JR, Castilho RM, Williams VP and
Gutkind JS: Semaphorin 4D provides a link between axon guidance
processes and tumor-induced angiogenesis. Proc Natl Acad Sci USA.
103:9017–9022. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tomizawa Y, Sekido Y, Kondo M, Gao B,
Yokota J, Roche J, Drabkin H, Lerman MI, Gazdar AF and Minna JD:
Inhibition of lung cancer cell growth and induction of apoptosis
after reexpression of 3p21. 3 candidate tumor suppressor gene
SEMA3B. Proc Natl Acad Sci USA. 98:13954–13959. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen CY, Chang YC, Chen LH, Lin WC, Lee
YH, Yeh ST, Chen HK, Fang W, Hsu CP, Lee JM, et al: The
extracellular SEMA domain attenuates intracellular apoptotic
signaling of semaphorin 6A in lung cancer cells. Oncogenesis.
7:952018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li X and Lee AY: Semaphorin 5A and
plexin-B3 inhibit human glioma cell motility through
RhoGDIalpha-mediated inactivation of Rac1 GTPase. J Biol Chem.
285:32436–32445. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sadanandam A, Sidhu SS, Wullschleger S,
Singh S, Varney ML, Yang CS, Ashour AE, Batra SK and Singh RK:
Secreted semaphorin 5A suppressed pancreatic tumour burden but
increased metastasis and endothelial cell proliferation. Br J
Cancer. 107:501–507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saxena S, Purohit A, Varney ML, Hayashi Y
and Singh RK: Semaphorin-5A maintains epithelial phenotype of
malignant pancreatic cancer cells. BMC Cancer. 18:12832018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sturn A, Quackenbush J and Trajanoski Z:
Genesis: Cluster analysis of microarray data. Bioinformatics.
18:207–208. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen J, Zhao J, Chen L, Dong N, Ying Z,
Cai Z, Ji D, Zhang Y, Dong L, Li Y, et al: STAT1 modification
improves therapeutic effects of interferons on lung cancer cells. J
Transl Med. 13:2932015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheriyath V, Kaur J, Davenport A, Khalel
A, Chowdhury N and Gaddipati L: G1P3 (IFI6), a mitochondrial
localised antiapoptotic protein, promotes metastatic potential of
breast cancer cells through mtROS. Br J Cancer. 119:52–64. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao M, Lin Y, Liu X, Li Y, Zhang C, Wang
Z, Wang Z, Wang Y and Guo Z: ISG20 promotes local tumor immunity
and contributes to poor survival in human glioma. Oncoimmunology.
8:e15340382019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luker KE, Pica CM, Schreiber RD and
Piwnica-Worms D: Overexpression of IRF9 confers resistance to
antimicrotubule agents in breast cancer cells. Cancer Res.
61:6540–6547. 2001.PubMed/NCBI
|
|
36
|
Park C, Li S, Cha E and Schindler C:
Immune response in Stat2 knockout mice. Immunity. 13:795–804. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wilderman MJ, Sun J, Jassar AS, Kapoor V,
Khan M, Vachani A, Suzuki E, Kinniry PA, Sterman DH, Kaiser LR and
Albelda SM: Intrapulmonary IFN-β gene therapy using an adenoviral
vector is highly effective in a murine orthotopic model of
bronchogenic adenocarcinoma of the lung. Cancer Res. 65:8379–8387.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yoo L, Yoon AR, Yun CO and Chung KC:
Covalent ISG15 conjugation to CHIP promotes its ubiquitin E3 ligase
activity and inhibits lung cancer cell growth in response to type I
interferon. Cell Death Dis. 9:972018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang JF, Chen Y, Lin GS, Zhang JD, Tang
WL, Huang JH, Chen JS, Wang XF and Lin ZX: High IFIT1 expression
predicts improved clinical outcome, and IFIT1 along with MGMT more
accurately predicts prognosis in newly diagnosed glioblastoma. Hum
Pathol. 52:136–144. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ghislain JJ, Wong T, Nguyen M and Fish EN:
The interferon-inducible stat2: Stat1 heterodimer preferentially
binds in vitro to a consensus element found in the promoters of a
subset of interferon-stimulated genes. J Interferon Cytokine Res.
21:379–388. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sadanandam A, Rosenbaugh EG, Singh S,
Varney M and Singh RK: Semaphorin 5A promotes angiogenesis by
increasing endothelial cell proliferation, migration, and
decreasing apoptosis. Microvasc Res. 79:1–9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sadanandam A, Varney ML, Singh S, Ashour
AE, Moniaux N, Deb S, Lele SM, Batra SK and Singh RK: High gene
expression of semaphorin 5A in pancreatic cancer is associated with
tumor growth, invasion and metastasis. Int J Cancer. 127:1373–1383.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Aranko AS, Oeemig JS, Kajander T and Iwaï
H: Intermolecular domain swapping induces intein-mediated protein
alternative splicing. Nat Chem Biol. 9:616–622. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shen L, Shi Q and Wang W: Double agents:
Genes with both oncogenic and tumor-suppressor functions.
Oncogenesis. 7:252018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fink K and Grandvaux N: STAT2 and IRF9:
Beyond ISGF3. JAKSTAT. 2:e275212013.PubMed/NCBI
|
